ATE118353T1 - Rekombinanter herpes simplex gb-gd impfstoff. - Google Patents

Rekombinanter herpes simplex gb-gd impfstoff.

Info

Publication number
ATE118353T1
ATE118353T1 AT85902226T AT85902226T ATE118353T1 AT E118353 T1 ATE118353 T1 AT E118353T1 AT 85902226 T AT85902226 T AT 85902226T AT 85902226 T AT85902226 T AT 85902226T AT E118353 T1 ATE118353 T1 AT E118353T1
Authority
AT
Austria
Prior art keywords
herpes simplex
vaccine
recombinant herpes
vaccines
hsv
Prior art date
Application number
AT85902226T
Other languages
English (en)
Inventor
Rae Lyn Burke
Carol Pachl
Pablo D T Valenzuela
Mickey S Urdea
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/631,669 external-priority patent/US4618578A/en
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE118353T1 publication Critical patent/ATE118353T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT85902226T 1984-04-06 1985-04-04 Rekombinanter herpes simplex gb-gd impfstoff. ATE118353T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59778484A 1984-04-06 1984-04-06
US06/631,669 US4618578A (en) 1984-07-17 1984-07-17 Expression of glycoprotein D of herpes simplex virus

Publications (1)

Publication Number Publication Date
ATE118353T1 true ATE118353T1 (de) 1995-03-15

Family

ID=27082907

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94202224T ATE230798T1 (de) 1984-04-06 1985-04-04 Rekombinanter herpes simplex gb-gd-impfstoff
AT85902226T ATE118353T1 (de) 1984-04-06 1985-04-04 Rekombinanter herpes simplex gb-gd impfstoff.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94202224T ATE230798T1 (de) 1984-04-06 1985-04-04 Rekombinanter herpes simplex gb-gd-impfstoff

Country Status (6)

Country Link
EP (2) EP0628633B1 (de)
AT (2) ATE230798T1 (de)
CA (1) CA1337181C (de)
DE (1) DE3587991T2 (de)
HK (1) HK107595A (de)
WO (1) WO1985004587A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US6100064A (en) * 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
DE3751772T2 (de) * 1986-10-20 1996-12-05 Chiron Corp Impfstoff zur behandlung von hsv
EP0297924A3 (de) * 1987-07-01 1990-07-11 City Of Hope Rekombinant vaccinia Virus zur Expression von HSV 1 gB
CA1335718C (en) * 1988-04-14 1995-05-30 Mary L. Haffey Expression of a functional form of a herpes virus dna polymerase in yeast
DK0405867T3 (da) * 1989-06-27 1995-05-22 Smithkline Beecham Biolog Hidtil ukendte forbindelser
CA2088600C (en) * 1990-08-02 1999-11-16 Rae L. Burke Herpes simplex virus vp16 vaccines
ATE196163T1 (de) 1990-10-04 2000-09-15 Res Corp Technologies Inc Varicella-zoster virusantigen
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US6193984B1 (en) 1992-02-03 2001-02-27 Cedars-Sinai Medical Center Pharmaceutical composition of herpes simplex virus typ-1 (HSV-1) glycoproteins
US5672349A (en) * 1992-02-03 1997-09-30 Cedars Sinai Medical Center Process for the expression of herpes simplex virus type 1 glycoprotein I and methods of use
US5955088A (en) * 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
CA2090295A1 (en) * 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
WO1996017938A1 (en) * 1994-12-06 1996-06-13 Bruschettini S.R.L. Glycoproteins from herpes virus and vaccines containing them
US6197497B1 (en) 1995-04-21 2001-03-06 University Of New Mexico Immunoassay for herpes simplex virus
KR100408817B1 (ko) * 1995-07-28 2004-02-25 주식회사 엘지생명과학 헤르페스심플렉스바이러스의당단백질을대량발현시키는동물세포주
EP2286792A1 (de) 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Mikroemulsionen mit einer adsorbierenden Oberfläche, enthaltend eine Mikrotropfenemulsion
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
EP2289547B1 (de) 2003-09-12 2015-12-16 Agenus Inc. Impfstoff zur Behandlung und Prävention der Herpes Simplex-Virusinfektion
AU2020283954B2 (en) * 2019-05-28 2026-04-30 Case Western Reserve University Compositions and methods for preserving DNA methylation
WO2021242872A1 (en) 2020-05-27 2021-12-02 Case Western Reserve University Compositions and methods for preserving dna methylation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228501A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens
JPS615786A (ja) * 1984-06-19 1986-01-11 Chemo Sero Therapeut Res Inst 単純ヘルペスウイルス遺伝子を組込んだ組換えｄｎａ、形質転換動物細胞および単純ヘルペスウイルス蛋白質の製法
DE3582200D1 (de) * 1984-07-20 1991-04-25 Chemo Sero Therapeut Res Inst Rekombinante dns, enthaltend ein herpes-simplex-virus-gen oder ein fragment davon, hefe transformiert mit dieser rekombinanten dns und verfahren zur herstellung von herpes-simplex-virus-proteinen.

Also Published As

Publication number Publication date
HK107595A (en) 1995-07-14
EP0175787B1 (de) 1995-02-15
EP0175787A1 (de) 1986-04-02
ATE230798T1 (de) 2003-01-15
DE3587991T2 (de) 1995-07-20
CA1337181C (en) 1995-10-03
DE3587991D1 (de) 1995-03-23
WO1985004587A1 (en) 1985-10-24
EP0628633A1 (de) 1994-12-14
EP0175787A4 (de) 1988-02-23
EP0628633B1 (de) 2003-01-08

Similar Documents

Publication Publication Date Title
ATE230798T1 (de) Rekombinanter herpes simplex gb-gd-impfstoff
IT8247706A0 (it) Procedimento per la produzione di virus vaccini
IT1164858B (it) Procedimento per la preparazione di vaccini a base di virus con proteine superficiali ricombinanti e prodotto ottenuto
DK603888D0 (da) Rekombinant virus
IT1241119B (it) Vaccino di poxvirus ricombinante di herpesvirus
FR2620459B1 (fr) Virus recombinant de la vaccine
DE10399032I1 (de) Rekombinante Viren.
NZ211880A (en) Immunogenic, leukemia-associated viral proteins and vaccines
ATE129160T1 (de) Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt.
DK479083D0 (da) Materialer og metoder til herpes simplex-virus-vaccination
ZA904915B (en) Varicella-zoster virus glycoproteins gpi,gpii and gpiii and their use in vaccines
DE3485873D1 (en) Herpes simplex virus subunitimpfstoff.
DE4192786T1 (de) Masernvirus-Rekombinanter Pockenvirus-Impfstoff
EP0289550A4 (de) Impfstoff zur behandlung von hsv.
FI811685A7 (fi) Menetelmä virusperäisten glykoproteiiniantigeenien eristämiseksi ja niiden käyttö rokotteiden vvalmistukseen.
NO964874L (no) Fusjonsglykoprotein fra HCMV og HSV
ES8800358A1 (es) Un procedimiento para preparar un polipeptido hibrido.
FI890116A0 (fi) Icke-reverterande rna-virus.
DK0389286T3 (da) Rekombinant-cytomegalovirus-vaccine
DK498387A (da) Virus-dna-sekvens
GB1538704A (en) Inactivated equine rhinopneumonitis virus vaccine
DK219187A (da) Rekombinant-virus
FI870501A0 (fi) Menetelmä melanoomaan liittyvän p97-antigeenin antigeenisen sukulaispeptidin tai -proteiinin valmistamiseksi, sekä siinä käyttökelpoiset yhdistelmävirukset, yhdistelmävektorit ja isäntäsolut
DE3134426A1 (de) Highly attenuated varicella virus vaccine and production thereof
ZA919198B (en) Measles virus recombinant poxvirus vaccine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time